Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

Availability, quality, and understandability of English and Spanish-language YouTube content on PSMA PET imaging for prostate cancer.

Clinical imaging·2026
Same author

Balancing Cure and Quality of Life: Navigating Functional Outcomes in Localized Prostate Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

The burden of Peyronie's disease on the female partner: a qualitative study.

The journal of sexual medicine·2026
Same author

Intimacy After Diagnosis: Navigating Sexual Health Conversations and Disparities Among Cancer Survivors.

The American journal of hospice & palliative care·2026
Same author

Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.

Cancer·2026
Same journal

Role and relevance of genetic testing in patients with kidney stones: a review from EAU Section of Endourology.

Current opinion in urology·2026
Same journal

Advances in evaluating and delivering nontechnical skills training: The use of simulation, robotics, artificial intelligence and virtual reality.

Current opinion in urology·2026
Same journal

Educating for a sustainable future: faculty and student perspectives and a review of environmental sustainability in medical education - an EAU endourology study.

Current opinion in urology·2026
Same journal

Shaping the future of endourology: role of education, simulation and uro-technology: a scoping review by the EAU Section of Endourology.

Current opinion in urology·2026
Same journal

A review of emerging technologies and techniques for percutaneous nephrolithotomy access.

Current opinion in urology·2026
Same journal

Artificial intelligence in kidney cancer: a review of clinical applications across the disease spectrum.

Current opinion in urology·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Prostate-specific antigen screening: pro.

Stacy Loeb1, William J Catalona

  • 1Brady Urological Institute, Johns Hopkins Medical Institutions, 600 N. Wolfe Street, Baltimore, MD 21231, USA. stacyloeb@gmail.com

Current Opinion in Urology
|March 13, 2010
PubMed
Summary
This summary is machine-generated.

Prostate-specific antigen (PSA) testing is a valid tool for screening prostate cancer, effectively reducing metastatic disease and improving survival rates. Evidence confirms PSA

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Experiment Videos

Last Updated: Jun 15, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Area of Science:

  • Urology
  • Oncology
  • Diagnostic Markers

Background:

  • Prostate cancer is a leading noncutaneous malignancy in US men.
  • Prostate-specific antigen (PSA) testing is a primary diagnostic method, yet its use is debated.
  • This review examines the evidence supporting PSA in prostate cancer screening.

Purpose of the Study:

  • To present evidence supporting the utility of PSA in prostate cancer screening.
  • To address the controversy surrounding PSA testing.
  • To highlight the role of PSA in assessing cancer aggressiveness.

Main Methods:

  • Review of epidemiologic evidence.
  • Analysis of randomized trial data.
  • Evaluation of studies correlating PSA levels with outcomes.

Main Results:

  • Serum PSA levels directly correlate with current and future prostate cancer risk.
  • Elevated PSA predicts adverse pathology and reduced disease-specific survival.
  • PSA screening is linked to decreased advanced disease and improved survival rates.
  • A randomized trial confirmed PSA testing reduces metastatic disease and mortality.

Conclusions:

  • Prostate-specific antigen (PSA) is a validated marker for prostate cancer and its aggressiveness.
  • Level 1 evidence demonstrates that PSA-based screening reduces metastatic disease.
  • PSA screening significantly lowers prostate cancer-specific mortality.